Trillium Therapeutics Inc R5WP-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 06/11/21 CEST
7.87quote price arrow down-0.15 (-1.82%)
52 week range
1.97 - 17.70

...

Loading . . .
  • Open7.81
  • Day High7.87
  • Day Low7.81
  • Prev Close8.02
  • 52 Week High17.70
  • 52 Week High Date11/30/20
  • 52 Week Low1.97
  • 52 Week Low Date07/24/20

Key Stats

  • Market Cap1,003.14M
  • Shares Out103.03M
  • 10 Day Average Volume262.83
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-24.67

KEY STATS

  • Open7.81
  • Day High7.87
  • Day Low7.81
  • Prev Close8.02
  • 52 Week High17.70
  • 52 Week High Date11/30/20
  • 52 Week Low1.97
  • 52 Week Low Date07/24/20
  • Market Cap1,003.14M
  • Shares Out103.03M
  • 10 Day Average Volume262.83
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-24.67

RATIOS/PROFITABILITY

  • EPS (TTM)-0.57
  • P/E (TTM)-13.81
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Trillium Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

Profile

MORE
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies....
Jan Skvarka Ph.D.
President
James Parsons CPA
Chief Financial Officer
Address
2488 Dunwin Dr
Mississauga, ON
L5L 1J9
Canada